Heffernan Michael Thomas
SEC-identified person · CIK 1448914 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Engene Therapeutics Inc. ENGN | Director | filed 2025 - 2026 |
| Cerecor Inc. CERC | Director | filed 2025 - 2026 |
| Trevi Therapeutics, Inc. TRVI | Director | filed 2019 - 2026 |
| Biohaven Ltd. BHVN | Director | filed 2022 - 2026 |
| Collegium Pharmaceutical, INC COLL | Director · Chairman/Pres/CEO | filed 2015 - 2025 |
| Synlogic, INC. SYBX | Director | filed 2020 - 2023 |
| Biohaven Pharmaceutical Holding Co Ltd. BHVN | Director | filed 2020 - 2022 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2018 - 2021 |
| Keryx Biopharmaceuticals INC KERX | Director | filed 2016 - 2018 |
| Ocata Therapeutics, Inc. OTCBB:ACTC | Director | filed 2012 - 2016 |
| Critical Therapeutics INC CTRX | Director | filed 2008 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.